Crinetics CEO exercises options for 19,928 shares
Crinetics Pharmaceuticals, Inc. reported that President & CEO Richard Scott Struthers exercised stock options on August 7, 2026 to acquire a total of 19,928 shares of common stock through four option exercises.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Crinetics Pharmaceuticals, Inc. reported that President & CEO Richard Scott Struthers exercised stock options on August 7, 2026 to acquire a total of 19,928 shares of common stock through four option exercises. The options had exercise prices of $25.19, $22.61, $20.02, and $15.29 per share. Indirect holdings include common stock held by multiple family trusts and a charitable trust, with examples such as 136,805 shares held by Family Trust 1 and 80,000 shares held by a Charitable Trust. No sales of common stock are reported in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 3,969 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F2 | 4,422 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3 | 6,542 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F4 | 4,995 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,969 | $25.19 | $100K |
| Exercise | Common Stock | 4,422 | $22.61 | $100K |
| Exercise | Common Stock | 6,542 | $15.29 | $100K |
| Exercise | Common Stock | 4,995 | $20.02 | $100K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. 1/48th of the shares subject to the option vested monthly.
- F2. 1/48th of the shares subject to the option vested on March 24, 2020, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- F3. 1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- F4. 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
Common Stock financial
Family Trust financial
Charitable Trust financial
indirect ownership financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CRNX CEO Richard Scott Struthers report in this Form 4?
How many Crinetics (CRNX) options did the CEO exercise and at what prices?
What indirect CRNX holdings does the CEO report through family trusts?
Does the Crinetics (CRNX) Form 4 involve a Rule 10b5-1 trading plan?
What vesting terms applied to the CRNX stock options exercised by the CEO?
AI-generated analysis. How Rhea-AI works. Not financial advice.